The Uromigos

Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer 08.11.2025 37:40 ↓

Brian leads a discussion of Rana McCay, Chris Sweeney and Michael Morris on the PSMAddition data and the landscape of radioligands in prostate cancer.

Episode 458: #UromigosLive 2025 - Mock ODAC 08.11.2025 45:22 ↓

Brian takes the role of the FDA and we conduct a mock ODAC on the CREST and POTOMAC data

Episode 457: #UromigosLive 2025: ADCs in Bladder Cancer 07.11.2025 56:48 ↓

Tom moderates Jun Guo, Matt Galsky, Michiel Van der Heidjen and Shilpa Gupta as they discuss this ever-expanding class of agents in bladder cancer.

Episode 456: #UromigosLive 2025: Peri-operative Therapy for Urothlial Cancer 07.11.2025 51:51 ↓

The first session from UromigosLive 2025! In this episode, Tom moderates as Jonathan Rosenberg, Matt Galsky, Kala Sridhar and Josh Meeks discuss the peri-operative space and the impact of the neoadjuvant EVP and other data.

Episode 455: ESMO 2025 Urothelial Cancer Review 23.10.2025 27:19 ↓

Tom and Brian discuss the bladder cancer highlights from ESMO 2025. Show throwing is discussed.

Episode 454: ESMO 2025 Prostate and Kidney Cancer Review 23.10.2025 46:15 ↓

Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025

Episode 453: ESMO 2025 - IMvigor011 20.10.2025 37:27 ↓

Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA

Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer 19.10.2025 42:51 ↓

Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

Episode 451: ESMO 2025 - PSMAddition 19.10.2025 30:31 ↓

Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC

Episode 450: ESMO 2025 - CAPITELLO 19.10.2025 21:35 ↓

Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025

Episode 449: ESMO 2025 - ENZARAD 19.10.2025 28:00 ↓

Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE

Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC 18.10.2025 46:21 ↓

Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!

Episode 447: ESMO 2025 - RAMPART 18.10.2025 36:41 ↓

James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC

Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets 18.10.2025 36:20 ↓

Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study

Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN) 17.10.2025 36:54 ↓

Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.

Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer 08.10.2025 41:58 ↓

Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025

Episode 443: ESMO 2025 Bladder Cancer Preview 02.10.2025 32:09 ↓

Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin

Episode 441: The History of IO in Urothelial Cancer - Part 2 29.09.2025 33:16 ↓

Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer

Episode 440: The History of IO in Urothelial Cancer - Part 1 22.09.2025 45:39 ↓

Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer

Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer 15.09.2025 41:24 ↓

Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.

Episode 438: The History of Testis Cancer Treatment 08.09.2025 39:22 ↓

Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.

Episode 436: The History of IO in RCC - Part 2 25.08.2025 36:29 ↓

We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

Episode 435: The History of IO in RCC - Part 1 18.08.2025 27:52 ↓

The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.

Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC 04.08.2025 48:51 ↓

Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.

Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap 21.07.2025 27:49 ↓

Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.